About
Dr. Sara El Hoss is an INSERM permanent researcher (CRCN) at Institut Imagine (Inserm U1163, Université Paris Cité) within the laboratory of Molecular Mechanisms of Hematological Disorders and Therapeutic Implications. After obtaining her PhD in Physiology and Pathophysiology from Université Paris Cité, she completed her postdoctoral trainings at INSERM and King's College London as a Marie Skłodowska-Curie Fellow before joining Institut Imagine as a FRM Post-Doctoral fellow and later one obtaining her position as an INSERM CRCN investigator. Her work has been recognized through several competitive national and international fellowships and grants. Beyond her research activities, she is actively involved in scientific leadership and communication within the international hematology community. Since 2024, she has served as Chair of the Basic Science Program of the Annual Sickle Cell and Thalassaemia Conference (ASCAT) and is Head of Communication for the French Red Cell Research Network (GR-Ex). She is also an Associate Editor of the British Journal of Haematology and is committed to fostering scientific collaborations, mentoring the next generation of researchers, and promoting advances in hematology through editorial activities and international scientific networks.
Scientific project
Dr. Sara El Hoss has made important contributions to the understanding of erythropoiesis and red blood cell disorders, with a particular focus on sickle cell disease. Her research has identified novel mechanisms driving ineffective erythropoiesis, demonstrating the contribution of inflammasome activation and inflammatory signalling to impaired erythroid differentiation and highlighting potential therapeutic targets. She has also contributed to advancing the understanding of erythropoietic defects in VEXAS syndrome and of the molecular pathways regulating erythroid maturation. By combining patient-derived samples with advanced cellular and molecular approaches, her work bridges fundamental discoveries with translational applications to improve the management of inherited hematological disorders.
Building on these discoveries, Dr. El Hoss currently leads several translational research programs aimed at improving our understanding of sickle cell disease and other hemoglobinopathies. Her research investigates the interplay between inflammation, hematopoietic stem cell biology, and erythropoiesis, with a particular focus on identifying innovative therapeutic strategies. She also leads one of the first comprehensive research programs exploring the impact of pregnancy on hematopoiesis and maternal–fetal adaptations in sickle cell disease. In parallel, her group studies the molecular regulation of fetal hemoglobin and erythroid differentiation, integrating patient-derived samples, advanced cellular models, and cutting-edge genomic technologies to accelerate the development of novel therapies for inherited red blood cell disorders.
2018Journal (source)Blood